Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial

被引：0

作者：

Yongliang Feng

Jing Chen

Tian Yao

Yue Chang

Xiaoqing Li

Rongqin Xing

Hong Li

Ruixue Xie

Xiaohong Zhang

Zhiyun Wei

Shengcai Mu

Ling Liu

Lizhong Feng

Suping Wang

机构：

[1] Shanxi Medical University,Department of Epidemiology, School of Public Health

[2] Shanxi Medical University,Center of Clinical Epidemiology and Evidence Based Medicine

[3] Shanxi Provincial Center for Disease Control and Prevention,undefined

[4] Shanxi Provincial Key Laboratory for Major Infectious Disease Response,undefined

[5] Outpatient Department of Shanxi Aviation Industry Group Co. LTD,undefined

来源：

Infectious Diseases of Poverty | / 10卷

关键词：

COVID-19; Inactivated SARS-CoV-2 vaccine; Immunogenicity; Safety; High-risk occupational population; Randomized controlled trial;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Xia, Shengli
Zhang, Yuntao
Wang, Yanxia
Wang, Hui
Yang, Yunkai
Gao, George Fu
Tan, Wenjie
Wu, Guizhen
Xu, Miao
Lou, Zhiyong
Huang, Weijin
Xu, Wenbo
Huang, Baoying
Wang, Huijuan
Wang, Wei
Zhang, Wei
Li, Na
Xie, Zhiqiang
Ding, Ling
You, Wangyang
Zhao, Yuxiu
Yang, Xuqin
Liu, Yang
Wang, Qian
Huang, Lili
Yang, Yongli
Xu, Guangxue
Luo, Bojian
Wang, Wenling
Liu, Peipei
Guo, Wanshen
Yang, Xiaoming
LANCET INFECTIOUS DISEASES, 2021, 21 (01): : 39 - 51
[42] Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial
Nawal Al Kaabi
Yun Kai Yang
Yu Liang
Ke Xu
Xue Feng Zhang
Yun Kang
Yu Qin Jin
Jun Wei Hou
Jing Zhang
Tian Yang
Salah Hussein
Mohamed Saif ElDein
Ze Hua Lei
Hao Zhang
Shuai Shao
Zhao Ming Liu
Ning Liu
Xiang Zheng
Ji Guo Su
Sen Sen Yang
Xiangfeng Cong
Yao Tan
Wenwen Lei
Xue Jun Gao
Zhiwei Jiang
Hui Wang
Meng Li
Hanadi Mekki Mekki
Walid Zaher
Sally Mahmoud
Xue Zhang
Chang Qu
Dan Ying Liu
Jing Zhang
Mengjie Yang
Islam Eltantawy
Peng Xiao
Fu Jie Shen
Jin Juan Wu
Zi Bo Han
Li Fang Du
Fang Tang
Shi Chen
Zhi Jing Ma
Fan Zheng
Ya Nan Hou
Xin Yu Li
Xin Li
Zhao Nian Wang
Jin Liang Yin
Signal Transduction and Targeted Therapy, 8
[43] Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study
Cai, Shaohang
Liao, Guichan
Yu, Tao
Gao, Qiqing
Zou, Lirong
Zhang, Huan
Xu, Xuwen
Chen, Juanjuan
Lu, Aili
Wu, Yingsong
Li, Baisheng
Peng, Jie
JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (09) : 4224 - 4233
[44] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18-55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial
Ansarifar, Akram
Farahani, Ramin Hamidi
Rahjerdi, Ahmad Karimi
Ahi, Mohammadreza
Sheidaei, Ali
Gohari, Kimiya
Rahimi, Zahra
Gholami, Fatemeh
Basiri, Pouria
Moradi, Milad
Jahangiri, Arash
Naderi, Kosar
Ghasemi, Soheil
Khatami, Pezhman
Honari, Mohsen
Khodaverdloo, Samane
Shooshtari, Mohammad
Azin, Hajar Mehr
Moradi, Sohrab
Shafaghi, Batool
Allahyari, Hossein
Monazah, Arina
Poor, Ali Khodaei
Bakhshande, Hooman
Taghva, Zahra
Nia, Mohammad Karimi
Dodaran, Masoud Solaymani
Foroughizadeh, Mohsen
VACCINE: X, 2023, 15
[45] Acceptance, safety, and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in patients with primary biliary cholangitis
Li, Haolong
Wang, Xu
Wang, Siyu
Feng, Xinxin
Wang, Li
Li, Yongzhe
HELIYON, 2024, 10 (07)
[46] Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India A Phase 2-3 Randomized Clinical Trial
Gunale, Bhagwat
Kapse, Dhananjay
Kar, Sonali
Bavdekar, Ashish
Kohli, Sunil
Lalwani, Sanjay
Meshram, Sushant
Raut, Abhishek
Kulkarni, Praveen
Samuel, Clarence
Munshi, Renuka
Gupta, Madhu
Plested, Joyce S.
Cloney-Clark, Shane
Zhu, MingZhu
Pryor, Melinda
Hamilton, Stephanie
Thakar, Madhuri
Shete, Ashwini
Dharmadhikari, Abhijeet
Bhamare, Chetanraj
Shaligram, Umesh
Poonawalla, Cyrus S.
Mallory, Raburn M.
Glenn, Gregory M.
Kulkarni, Prasad S.
JAMA PEDIATRICS, 2023, 177 (09) : 911 - 920
[47] The immunogenicity of Alum plus CpG adjuvant SARS-CoV-2 inactivated vaccine in mice
Yang, Jie
Li, Boran
Yang, Dongsheng
Wu, Jie
Yang, Anna
Wang, Wenhui
Lin, Fengjie
Wan, Xin
Li, YuWei
Chen, Zhuo
Lv, Shiyun
Pang, Deqin
Liao, Wenbo
Meng, Shengli
Lu, Jia
Guo, Jing
Wang, Zejun
Shen, Shuo
VACCINE, 2023, 41 (41) : 6064 - 6071
[48] Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials
Lim, Hui Xuan
Arip, Masita
Yahaya, Abdul Aziz Al-Fattah
Jazayeri, Seyed Davoud
Poppema, Sibrandes
Poh, Chit Laa
FRONTIERS IN BIOSCIENCE-LANDMARK, 2021, 26 (11): : 1286 - 1304
[49] Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C in adults previously vaccinated with inactivated vaccine: A randomized, double-blind, placebo-controlled phase 1/2 clinical trial
Hannawi, Suad
Saifeldin, Linda
Abuquta, Alaa
Alamadi, Ahmad
Mahmoud, Sally A.
Li, Jian
Chen, Yuanxin
Xie, Liangzhi
JOURNAL OF INFECTION, 2023, 86 (02) : 170 - 172
[50] Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial
Zhu, Dandan
Hu, Yuansheng
Jiang, Zhiwei
Yang, Tuantuan
Chu, Kai
Zhang, Hengming
Hu, Jialei
Meng, Xing
Tan, Zhijun
Wu, Jingliang
Lian, Xiaojuan
Li, Changgui
Pan, Hongxing
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)

← 1 2 3 4 5 →